中国临床药学杂志

参考文献

[1] Suzatani T,Machida H,Sukuma T,et al. Effects of variousnucleosides on antiviral acitivity and metabolism of 1-β-D-arabino-furanosyl-E-5 (2 -bromovinyl) uracil againstherps 1and2 .Antimicrob Agents Chemother,1988,32 :15 47

[2 ] Lin JC,Machida H. Comparison of two bromovinyl nucleosideanalogs,1-β-D-arabino-furanosyl-E-5 (2 -bromovinyl ) -2 -deoxyuridine,with acyclovir in inhibition of Epstein-Barr virusreplication.Antimicrob Agents Chem other,1988,32 :10 6 8

[3] Machida H,Nishitani M. Drug susceptibilities of isolates ofvaricella-zoster virus in a clinical study of oral brovavir.Microbiol Immunol,1990 ,34:40 7

[4] Nakamura H,Omori S,Kitada K,et al. Prevention of druginteractions and its countermeasure.JToxicol Sci,1994,19:89

[5 ] Okuda H,Nishiyama T,Ogura K,et al. L ethal druginteractions of sorivudine,a new antiviral drug,with oral 5 -fluorouracil prodrugs. Drug-Metab-Dispos,1997,2 5 (5 ) :2 70

[6 ] Daher GC,Harris BE,Diasio RB.Metabolism of pyrimidineanalogues and their nucleosides,In:Metabolism and reactionsof anticancer drugs,Vol. 1,In the International Encyclopediof Pharmacology and Therapeutics,Oxford,pergamon Press,1994,Chap2

[7] Yan J,Tyring SK,Mc Crary MM,et al. The effect ofsorivudine on dihydropyrimidine dehydrogenase activity inpatients with acute herpes zoster. Clin Pharmacol Ther,1997,6 1:5 6 3

[8] Johnson MJ,Yan J,Albin N,et al. Rapid Screening forDihydropyrim idine Dehydrogenase (DPD ) Deficiency,ACondition Associated with 5 -Fluorouracil Toxicity. Jchromatography Biomed Applications,1997,6 96 :183

[9] Spector T,Porter DJT,Nelson DJ,et al. 5 -Ethynyluracil(776 C85 ) ,a modulator of the therapeutic activity of 5 -fluorouacil.Drugs of the Future,1994,19:5 6 6

[10 ] Harris BE,Song R,He Y,etal. Circadian rhythm of rat liverdihydropyrimidine dehydrogenase:Possible relevance toflourophrimindine chem otherapy.Biochem Pharmacol,1988,37:475 9